


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which:

X is C₁₋₆alkyl or OR⁶;

Y is selected from hydrogen, halogen, CN, nitro, SO₂R³, OR⁴, SR⁴, SOR³, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁶SO₂R³, NR⁶CO₂R⁶, NR⁶COR³, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR⁶ and NR⁶R⁷, S(O)_nR⁶, n is 0, 1 or 2;

Z is phenyl optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, OH, SH, nitro, COR⁹, CO₂R⁶, SO₂R⁹, OR⁹, SR⁹, SOR⁹, SO₂NR¹⁰R¹¹,

CONR¹⁰R¹¹, NR¹⁰R¹¹, NHSO₂R⁹, NR⁹SO₂R⁹, NR⁶CO₂R⁶, NHCOR⁹, NR⁹COR⁹, NR⁶CONR⁴R⁵, NR⁶SO₂NR⁴R⁵, aryl,

C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, OR⁶, NR⁶R⁷, S(O)_nR⁶, CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷.

R¹ and R² independently represent a hydrogen atom, halogen, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or a C₁₋₆alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen,

C₃-C₇ cycloalkyl, NR⁶R⁷, OR⁶, S(O)_nR⁶,

R³ represents C₃-C₇ cycloalkyl or C₁₋₆alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, OR⁶ and NR⁶R⁷, S(O)_nR⁶, CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

R⁴ and R⁵ independently represent hydrogen, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, OR⁶ and NR⁶R⁷, S(O)_nR⁶, CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

R⁶ and R⁷ independently represents a hydrogen atom or C₁-C₆ alkyl;

R⁸ is hydrogen, C₁₋₄ alkyl, -COC₁-C₄ alkyl, CO₂C₁-C₄alkyl or CONR⁶C₁-C₄alkyl;

R⁹ represents aryl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, aryl, OR⁶ and NR⁶R⁷, S(O)_nR⁶, CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

R¹⁰ and R¹¹ independently represent aryl, hydrogen, C₃-C₇ cycloalkyl or

C₁-alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, aryl, OR⁶ and NR⁶R⁷, S(O)_nR⁶, CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷.

2. (Previously Presented) A compound according to claim 1 in which R¹ and R² independently represent a hydrogen atom, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or a C₁-alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, NR⁶R⁷, OR⁶, S(O)_nR⁶.

3. (Previously presented) A compound according to claim 1 in which X is C₁-alkyl or C₁-alkoxy.

4. (Previously presented) A compound according to claim 1 in which Y is hydrogen.

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1 in which Z is substituted by one or more substituents independently selected from halogen, C₁-alkyl, cyano and SO₂R⁹.

7. (Previously presented) A compound according to claim 1 in which R¹ and R² are both hydrogen or one is hydrogen and the other is C₁-3 alkyl.

8. (Previously presented) A compound according to claim 1 selected from:

[(5-Methylbiphenyl-2-yl)oxy]acetic acid,

{[5-Ethyl-4'-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,

{[4'-(Ethylsulfonyl)-5-methoxybiphenyl-2-yl]oxy}acetic acid,

[[4-Chloro-4'-(ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[4'-(Ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

2-[[3'-Cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[2'-Fluoro-5'-cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

and pharmaceutically acceptable salts thereof.

Claims 9-11 (Cancelled)

12. (Currently Amended) A method of treating The method of claim 11, wherein the respiratory disease is asthma or rhinitis, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.

13. (Previously presented) A compound according to claim 2 in which X is C₁₋₄alkyl or C₁₋₄alkoxy.

14. (Previously presented) A compound according to claim 2 in which Y is hydrogen.

15. (Cancelled)

16. (Previously presented) A compound according to claim 2 in which Z substituted by one or more substituents independently selected from halogen, C₁₋₃alkyl, cyano and SO₂R⁹.

17. (Previously presented) A compound according to claim 2 in which R¹ and R² are both hydrogen or one is hydrogen and the other is C₁₋₃alkyl.

18. (Previously presented) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent, or carrier.

19. (New) A method of producing a CRTh2 receptor inhibitory effect in a patient, which comprises administering to the patient an effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.